On August 18, 2025, the Technology Development Board (TDB)—under India’s Department of Science and Technology—entered into an agreement with Primary Healthtech Pvt. Ltd., a New Delhi-based company founded by IIT Guwahati alumni, for the development of an IoT-enabled, AI/ML-powered, point-of-care blood testing device aimed at making diagnostics affordable and accessible in primary healthcare settings.
The device, called Mobilab, is a portable, battery-operated clinical chemistry analyzer, capable of testing over 25 health parameters, including indicators for kidney, liver, heart health, vitamins, and cancer. It has already been trialed with 10,000 patients, holds a CDSCO manufacturing license, and includes a patented “transmittance-based system/kit for point-of-care quantification” transferred from IIT Guwahati, along with six additional patent applications.
The upgraded M1 prototype will be enhanced to handle five simultaneous tests, reducing wait time and enabling commercial-scale manufacturing. The tests will include:
Haemoglobin
Creatinine
Bilirubin
Cholesterol
Triglycerides
Uric acid
Glucose
Gamma-glutamyl transferase (GGT)
This initiative underscores India’s strategic push for Atmanirbhar Bharat—fostering indigenous innovation in medical technology.
As stated by Secretary Rajesh Kumar Pathak (TDB): “Ensuring quality healthcare access in rural and remote regions is a national priority. This project not only addresses affordability and accessibility but also demonstrates India’s capability in developing indigenous, AI-powered diagnostic solutions for primary healthcare.”
Primary Healthtech sees TDB’s support as a major push to transition from lab innovation to large-scale deployment, aiming to bridge healthcare gaps in rural and underserved areas.